NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size, Share, Trends, Growth, Forecast Analysis Report 2019 By Product, By Application, By Segment, By Region - Global Forecast To 2025
Report ID: MN0135954 | Published: Oct-2019 | No of Pages: 101
Format: pdf
The global market size of NASH (Non-alcoholic Steatohepatitis) Biomarkers is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of 2024 with a CAGR of XX% from 2019 to 2024.
Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Report 2019 - Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global NASH (Non-alcoholic Steatohepatitis) Biomarkers industry. The key insights of the report:
1.The report provides key statistics on the market status of the NASH (Non-alcoholic Steatohepatitis) Biomarkers manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.
2.The report provides a basic overview of the industry including its definition, applications and manufacturing technology.
3.The report presents the company profile, product specifications, capacity, production value, and 2013-2018 market shares for key vendors.
4.The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.
5.The report estimates 2019-2024 market development trends of NASH (Non-alcoholic Steatohepatitis) Biomarkers industry.
6.Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out
7.The report makes some important proposals for a new project of NASH (Non-alcoholic Steatohepatitis) Biomarkers Industry before evaluating its feasibility.
There are 4 key segments covered in this report: competitor segment, product type segment, end use/application segment and geography segment.
For competitor segment, the report includes global key players of NASH (Non-alcoholic Steatohepatitis) Biomarkers as well as some small players. At least 10 companies are included:
* GENFIT SA
* Gilead Sciences
* Inc. (GILD)
* AstraZeneca
* Novartis AG
* Bristol-Myers Squibb Company
For complete companies list, please ask for sample pages.
The information for each competitor includes:
* Company Profile
* Main Business Information
* SWOT Analysis
* Sales, Revenue, Price and Gross Margin
* Market Share
For product type segment, this report listed main product type of NASH (Non-alcoholic Steatohepatitis) Biomarkers market
* Serum biomarkers
* Hepatic fibrosis biomarkers
* Apoptosis biomarkers
* Oxidative stress biomarkers
* Others
For end use/application segment, this report focuses on the status and outlook for key applications. End users are also listed.
* Pharma & CRO Industry
* Hospitals
* Diagnostic Labs
* Academic Research Institutes
For geography segment, regional supply, application-wise and type-wise demand, major players, price is presented from 2013 to 2023. This report covers following regions:
* North America
* South America
* Asia & Pacific
* Europe
* MEA (Middle East and Africa)
The key countries in each region are taken into consideration as well, such as United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc.
Reasons to Purchase this Report:
* Analyzing the outlook of the market with the recent trends and SWOT analysis
* Market dynamics scenario, along with growth opportunities of the market in the years to come
* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and non-economic aspects
* Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
* Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
* 1-year analyst support, along with the data support in excel format.
We also can offer customized report to fulfill special requirements of our clients. Regional and Countries report can be provided as well.
Table of Content
Chapter 1 Executive Summary
Chapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Methodology
3.2.1 Primary Sources
3.2.2 Secondary Sources
3.2.3 Assumptions
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 Introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
Chapter 6 Industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Trading Analysis
8.1 Export of NASH (Non-alcoholic Steatohepatitis) Biomarkers by Region
8.2 Import of NASH (Non-alcoholic Steatohepatitis) Biomarkers by Region
8.3 Balance of Trade
Chapter 9 Historical and Current NASH (Non-alcoholic Steatohepatitis) Biomarkers in North America (2013-2018)
9.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Supply
9.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Demand by End Use
9.3 Competition by Players/Suppliers
9.4 Type Segmentation and Price
9.5 Key Countries Analysis
9.5.1 US
9.5.2 Canada
9.5.3 Mexico
Chapter 10 Historical and Current NASH (Non-alcoholic Steatohepatitis) Biomarkers in South America (2013-2018)
10.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Supply
10.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Demand by End Use
10.3 Competition by Players/Suppliers
10.4 Type Segmentation and Price
10.5 Key Countries Analysis
10.5.1 Brazil
10.5.2 Argentina
10.5.3 Chile
10.5.4 Peru
Chapter 11 Historical and Current NASH (Non-alcoholic Steatohepatitis) Biomarkers in Asia & Pacific (2013-2018)
11.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Supply
11.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Demand by End Use
11.3 Competition by Players/Suppliers
11.4 Type Segmentation and Price
11.5 Key Countries Analysis
11.5.1 China
11.5.2 India
11.5.3 Japan
11.5.4 South Korea
11.5.5 ASEAN
11.5.6 Australia
Chapter 12 Historical and Current NASH (Non-alcoholic Steatohepatitis) Biomarkers in Europe (2013-2018)
12.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Supply
12.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Demand by End Use
12.3 Competition by Players/Suppliers
12.4 Type Segmentation and Price
12.5 Key Countries Analysis
12.5.1 Germany
12.5.2 France
12.5.3 UK
12.5.4 Italy
12.5.5 Spain
12.5.6 Belgium
12.5.7 Netherlands
12.5.8 Austria
12.5.9 Poland
12.5.10 Russia
Chapter 13 Historical and Current NASH (Non-alcoholic Steatohepatitis) Biomarkers in MEA (2013-2018)
13.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Supply
13.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Demand by End Use
13.3 Competition by Players/Suppliers
13.4 Type Segmentation and Price
13.5 Key Countries Analysis
13.5.1 Egypt
13.5.2 Iran
13.5.3 Israel
13.5.4 South Africa
13.5.5 GCC
13.5.6 Turkey
Chapter 14 Summary for Global NASH (Non-alcoholic Steatohepatitis) Biomarkers (2013-2018)
14.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Supply
14.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Demand by End Use
14.3 Competition by Players/Suppliers
14.4 Type Segmentation and Price
Chapter 15 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecast (2019-2023)
15.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Supply Forecast
15.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Demand Forecast
15.3 Competition by Players/Suppliers
15.4 Type Segmentation and Price Forecast
Chapter 16 Analysis of Global Key Vendors
16.1 GENFIT SA
16.1.1 Company Profile
16.1.2 Main Business and NASH (Non-alcoholic Steatohepatitis) Biomarkers Information
16.1.3 SWOT Analysis of GENFIT SA
16.1.4 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2014-2019)
16.2 Gilead Sciences
16.2.1 Company Profile
16.2.2 Main Business and NASH (Non-alcoholic Steatohepatitis) Biomarkers Information
16.2.3 SWOT Analysis of Gilead Sciences
16.2.4 Gilead Sciences NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2014-2019)
16.3 Inc. (GILD)
16.3.1 Company Profile
16.3.2 Main Business and NASH (Non-alcoholic Steatohepatitis) Biomarkers Information
16.3.3 SWOT Analysis of Inc. (GILD)
16.3.4 Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2014-2019)
16.4 AstraZeneca
16.4.1 Company Profile
16.4.2 Main Business and NASH (Non-alcoholic Steatohepatitis) Biomarkers Information
16.4.3 SWOT Analysis of AstraZeneca
16.4.4 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2014-2019)
16.5 Novartis AG
16.5.1 Company Profile
16.5.2 Main Business and NASH (Non-alcoholic Steatohepatitis) Biomarkers Information
16.5.3 SWOT Analysis of Novartis AG
16.5.4 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2014-2019)
16.6 Bristol-Myers Squibb Company
16.6.1 Company Profile
16.6.2 Main Business and NASH (Non-alcoholic Steatohepatitis) Biomarkers Information
16.6.3 SWOT Analysis of Bristol-Myers Squibb Company
16.6.4 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2014-2019)
16.7 Allergan Plc
16.7.1 Company Profile
16.7.2 Main Business and NASH (Non-alcoholic Steatohepatitis) Biomarkers Information
16.7.3 SWOT Analysis of Allergan Plc
16.7.4 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2014-2019)
